|Biotechnology is now again making a new milestone by making the technology wearable. / Photo by: dolgachov via 123RF|
Biotech investors who like to see breakout upstarts coming are probably watching Endonovo Therapeutics, Inc. closely right now. It’s a commercial developer of non-invasive, wearable Electroceuticals. It’s, perhaps, the most hyped wearable on the market right now because it represents such a giant leap forward in biotech being watched in real time since about 2016. The Electroceutical is worn on the fingertip to administer pulsed, short-wave radiofrequencies that can heal certain kinds of injury, alleviate certain kinds of pain, assuage post-surgical edema and address central nervous system disorders. Both new and old research indicates that drugs may not have to be injected or swallowed in the future but, rather, reduced to “electrodrugs,” as they might be called, and transmitted in wave form to targeted points in the body with the requisite accuracy to deal directly with the target problem.
|The first experiment was done by researchers at the University of California in Berkeley. / Photo by: Mariusz Jurgielewicz via 123RF|
Back in 2016, engineers at the University of California, Berkeley revealed that they had contrived a first-in-kind, dust-size sensor that could be wirelessly implanted within the body. The results of the study led people to start speculating about what wearables like Fitbit could do with the integration of this technology. That was the kind of speculation that came at the time because of the sensor’s ability to monitor muscles, nerves, and organs in real time. It was an obvious game-changer coming down the pike, and these things were both wireless and batteryless. Over time, researchers have begun thinking bigger, and that’s where the concept for the Electroceutical comes in. The bigger picture was that these sensors represented a new opportunity to stimulate the immune system, treat disorders like epilepsy or taper inflammation.
“I think the long-term prospects for neural dust are not only within nerves and the brain but much broader,” Michel Maharbiz said as one of the two engineers on the project back in 2016. “Having access to in-body telemetry has never been possible because there has been no way to put something super tiny super deep. But now I can take a speck of nothing and park it next to a nerve or organ, your GI tract or a muscle, and read out the data.” Fast-forward to the present when Endonovo has already put a year of exciting market maneuvers under its belt, they’ve received approval from the U.S. Food and Drug Administration for applying their Electroceuticals to palliative treatment of soft-tissue injuries and post-op edema or pain.
Electroceuticals restore vital electrochemical processes that basically launch growth factor declines and anti-inflammatory drops so that healing can happen. Endonovo recently announced enrolling the first patient in a clinical study for treating traumatic brain injury at the University of New Mexico. A newly published, first-in-kind study, though, demonstrates the electrochemical activation of prodrugs, which are medications that get naturally metabolized into what then pharmacologically classifies as an active drug after metabolism has affected it. By industry standards, they’re not drugs upon administration, but they meet the standards that constitute a drug after undergoing the biochemical process. Researchers from the University of Edinburgh found that metal-based prodrugs could be activated remotely via electroceuticals.
In the study, they actually demonstrate how they don’t need the body’s metabolism and how they can target locations with pinpoint accuracy. They control the activation of a drug near a target cell, and they activate it while regulating how much active drug they generate and where to send it. They write that this method “is stable in biological complex media, for platinum-based prodrugs” and that its “efficacy in generating cytotoxic Pt(II) species [has been] examined in cell culture. The system retained its activating function within biological milieu and is amenable to miniaturization for implantation directly into a tumor. Stereotactic placement of miniaturized electrochemical devices within a tumor, as part of the Implantable Microsystems for Personalized Anti-Cancer Therapy (IMPACT) project, could provide unequivocal control over prodrug activation in a site-selective, time-dependent and localized mediated manner.”
This only bolsters Endonovo’s perception among many market experts as a stock destined to soar soon. It’s not only the fact that this application and proof of concept are now available to the public but more so the fact that it signifies just how many studies are being conducted by peoples and institutions completely unattached to Endonovo using this technology. Electroceuticals are now being seen as a means to do all sorts of things. The stock [ENDV] is 400 percent off its 52-week peak, and its downward trend for the last few months (save for small spikes here and there) suggest to some that a leap is forthcoming. Even now, the U.K. research team has plans to further study how to expedite the reduction rate of one of the drugs they used in their study on the part of the electrode surface’s nano-structuring.
|The first test for Electroceuticals will be for curing chronic kidney diseases. / Photo by: gopixa via 123RF|
Endonovo is now announcing that it plans to operate a new, bigger clinical study to analyze its Electroceutical Therapy for treating chronic kidney disease. They just highlighted the results of a feasibility study for the use of that same trademark therapy in mitigating proteinuria in patients who already have chronic kidney disease. While they focus on this, their product’s curb appeal soars as the global scientific community researches how best to apply their technology to other things like cancer or cardiovascular disease.